A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

NCT02004522 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

319

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Duvelisib
DRUG: Ofatumumab

Sponsor

SecuraBio